Ítem
Solo Metadatos

Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: A pilot study

Mostrar el registro sencillo de la publicación
dc.creatorArevalo, J. Fernandospa
dc.creatorSanchez, Juan G.spa
dc.creatorGarcia, Reinaldo A.spa
dc.creatorWu, Lihtehspa
dc.creatorBerrocal, Maria H.spa
dc.creatorRodriguez, Francisco J.spa
dc.creatorRodríguez, Alvarospa
dc.creatorNovoa, Liliana Andreaspa
dc.creatorGarcia-Amaris, Rafaelspa
dc.date.accessioned2020-05-26T00:09:41Z
dc.date.available2020-05-26T00:09:41Z
dc.date.created2007spa
dc.description.abstractBackground: The purpose of this study was to determine the feasibility, safety and clinical effect of indocyanine green (ICG)-mediated photothrombosis (IMP) combined with intravitreal triamcinolone acetonide (IVTA) in patients with macular edema secondary to idiopathic parafoveal telangiectasis (IPFT) group 2A without choroidal neovascularization (CNV). Methods: Nine eyes of six patients that were treated with IMP immediately followed by IVTA at a dose of 4 mg participated in the study. Patients had a mean follow-up of 23.3 months (range 12-36 months). Patients underwent one or two sessions of IMP combined with IVTA ('study group'). An IVTA-only group of 19 eyes from 14 patients with macular edema secondary to IPFT group 2A that underwent an IVTA 4 mg without IMP ('IVTA-only group') was included for comparison. In addition, a matched control group of 40 eyes from 20 patients selected retrospectively from our medical records with macular edema secondary to IPFT group 2A without any therapy was included ('observation group'). Results: The best-corrected visual acuity (BCVA) remained stable in five eyes (55.5%). Four eyes (44.4%) demonstrated improvement of BCVA (? two ETDRS lines), and no eyes experienced worsening of visual acuity (? two ETDRS lines). A significant decrease in hyperfluorescence was not seen with fluorescein angiography (FA), however optical coherence tomography (OCT) showed a decrease in the size of inner intraretinal hyporeflective spaces or cystic edema. Two (22.2%) eyes developed an increase in intraocular pressure. However, it was medically controlled with topical anti-glaucoma medications. Cataract developed in five eyes (55.5%). Six of nine eyes (66.6%) required one retreatment during the study period. At the last follow-up (mean 21.1 months, range 12-30 months) in the IVTA-only group, 5 (25.3%) eyes improved BCVA, 11 (57.9%) eyes remained within two lines of baseline BCVA and 3 (15.8%) eyes lost BCVA. In the observation group, with similar follow-up, 87.5% of eyes showed either stabilization or deterioration of BCVA over time. Conclusions: Combined IMP and IVTA may provide stability or improvementin BCVA and fundus findings in eyes with macular edema secondary to IPFT group 2A without CNV at a minimum follow-up of 12 months. © Springer-Verlag 2007.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/s00417-007-0633-2
dc.identifier.issn0721832X
dc.identifier.issn1435702X
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24172
dc.language.isoengspa
dc.relation.citationEndPage1680
dc.relation.citationIssueNo. 11
dc.relation.citationStartPage1673
dc.relation.citationTitleGraefe`s Archive for Clinical and Experimental Ophthalmology
dc.relation.citationVolumeVol. 245
dc.relation.ispartofGraefe's Archive for Clinical and Experimental Ophthalmology, ISSN:0721832X, 1435702X, Vol.245, No.11 (2007); pp. 1673-1680spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-34848823140&doi=10.1007%2fs00417-007-0633-2&partnerID=40&md5=2dd4d321067bf1bfc4a3741531458f1bspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAntiglaucoma agentspa
dc.subject.keywordoptical coherenceeng
dc.subject.keywordTriamcinolone acetonidespa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordArticlespa
dc.subject.keywordCataractspa
dc.subject.keywordClinical articlespa
dc.subject.keywordControlled studyspa
dc.subject.keywordFeasibility studyspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescence angiographyspa
dc.subject.keywordFollow upspa
dc.subject.keywordHumanspa
dc.subject.keywordIdiopathic parafoveal telangiectasis group 2aspa
dc.subject.keywordIndocyanine green mediated photothrombosisspa
dc.subject.keywordIntraocular hypertensionspa
dc.subject.keywordIntraocular pressurespa
dc.subject.keywordLow level laser therapyspa
dc.subject.keywordMalespa
dc.subject.keywordMedical recordspa
dc.subject.keywordOptical coherence tomographyspa
dc.subject.keywordPilot studyspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRetina macula edemaspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordSafetyspa
dc.subject.keywordSubretinal neovascularizationspa
dc.subject.keywordTelangiectasiaspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordAgedspa
dc.subject.keywordChoroidal neovascularizationspa
dc.subject.keywordColoring agentsspa
dc.subject.keywordCombined modality therapyspa
dc.subject.keywordFeasibility studiesspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescein angiographyspa
dc.subject.keywordFovea centralisspa
dc.subject.keywordGlucocorticoidsspa
dc.subject.keywordHumansspa
dc.subject.keywordIndocyanine greenspa
dc.subject.keywordInjectionsspa
dc.subject.keywordMacular edemaspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPhotochemotherapyspa
dc.subject.keywordPilot projectsspa
dc.subject.keywordRetinal diseasesspa
dc.subject.keywordTelangiectasisspa
dc.subject.keywordTomographyeng
dc.subject.keywordTreatment outcomespa
dc.subject.keywordTriamcinolone acetonidespa
dc.subject.keywordVisual acuityspa
dc.subject.keywordVitreous bodyspa
dc.subject.keywordGroup 2aspa
dc.subject.keywordIdiopathic parafoveal telangiectasisspa
dc.subject.keywordImpspa
dc.subject.keywordIndocyanine greenspa
dc.subject.keywordIntravi trealtriamcinolonespa
dc.subject.keywordMacular edemaspa
dc.subject.keywordPhotothrombosisspa
dc.titleIndocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: A pilot studyspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos